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Acute administration of L-arginine does not improve arterial Atherosclerosis remains the leading cause of death in
endothelial function in chronic renal failure. patients with renal failure [1]. Endothelial dysfunction
Background. Reduced activity of the nitric oxide (NO) path- resulting in reduced bioavailability of nitric oxide (NO)way has been implicated in the endothelial dysfunction that
has been implicated in the pathogenesis of uremic vascu-occurs in patients with renal failure. NO is generated from
lopathy [2]. In addition to its dilator effect, NO reducesl-arginine by NO synthase, and certain uremic toxins including
asymmetrical dimethyl-l-arginine (ADMA), inhibit NO syn- adhesion and aggregation of circulating cells, regulates
thase and might contribute to endothelial dysfunction. We hy- endothelial permeability and inhibits smooth muscle
pothesized that exogenous l-arginine might improve endothe- proliferation, properties consistent with an anti-athero-lial function in patients with renal failure by overcoming the
genic role. In experimental animals, reduced NO bio-effects of uremic toxins.
activity accelerates atherogenesis [3], and strategies toMethods. Endothelial function of the forearm resistance vas-
culature was assessed using plethysmography to measure the increase NO are anti-atherogenic [4]. Reduced bioactiv-
dilator response to intra-arterial acetylcholine (25 to 100 nmol/ ity of the NO pathway has been demonstrated in patients
min). Endothelial function of radial and brachial arteries was
with renal impairment [5–7]. The mechanism is unclearassessed using vascular ultrasound to measure the dilator re-
but may include reduced activity of NO synthase (NOS;sponse to flow during reactive hyperemia (flow-mediated dila-
tion; FMD). Studies were performed before and after adminis- secondary to reduced substrate or co-factors), or inhibi-
tration of l-arginine by intra-arterial infusion (50 mol/min) tion of NOS by endogenous inhibitors.
in 8 pre-dialysis patients or by intravenous infusion (10 g) in NGNGdimethyl-l-arginine (asymmetrical dimethylar-18 hemodialysis patients.
ginine; ADMA) is a potent naturally occurring NOS in-Results. Local l-arginine did not improve the dilator re-
hibitor [8]. Plasma concentrations are raised fourfold insponse of forearm resistance vessels (AUC 23.1  6.4 pre,
23.1  5.1 post; P  0.9) or FMD of the radial artery (6.5  patients with renal failure [9] but its impact on endothe-
1.2% pre, 6.3  0.8% post; P  0.8). Systemic l-arginine did lial function remains to be determined [10]. In this study
not improve FMD of the brachial artery (4.1 1.1% pre, 3.0
we have tested the hypothesis that in renal failure,1.1% post; P  0.07). These data demonstrate that acute local
NO-dependent dilation might be improved by acute sup-or systemic administration of l-arginine did not improve endo-
thelial function in resistance or conduit arteries of patients plementation with l-arginine to overcome competitive
with chronic renal failure. inhibition of NOS by ADMA and other uremic toxins.
Conclusion. The results suggest that competitive inhibition
of nitric oxide synthase (NOS) by circulating inhibitors is not
the principal explanation for impaired endothelial dilator func- METHODS
tion in chronic renal failure.
Subjects
Eighteen subjects receiving hemodialysis and 8 sub-
jects with severe chronic renal failure prior to the initia-
tion of renal replacement therapy were investigated. Pa-
tients were excluded if aged 70 years of age, had aKey words: atherosclerosis, vascular function, renal failure, nitric oxide,
uremic vasculopathy, ADMA. history of smoking, diabetes or a fasting cholesterol of
6 mmol/L; all of these are recognized independent riskReceived for publication April 18, 2001
factors for impaired endothelial function. As part of theirand in revised form July 12, 2001
Accepted for publication July 16, 2001 regular medication patients were being treated with an
average of two antihypertensive agents [22%  blockers, 2001 by the International Society of Nephrology
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56%  blockers, 72% calcium channel blockers, 56% arm was cannulated with a 27-gauge needle (Cooper’s
angiotensin-converting enzyme (ACE) inhibitors, 6% on Needle Works) inserted under local anesthesia (2 mL of
potassium channel openers and 22% on loop diuretics]. 1% lignocaine). Drug or saline (sodium chloride 0.9%
Regular medications were continued, though subjects wt/vol) were infused continuously at 0.5 mL/min. During
were asked to omit nitrates for the 48-hour period prior recording periods, the hands were excluded from the
to study. These studies were approved by University circulation by inflation of wrist cuffs to 200 mm Hg [12].
College London and Great Ormond Street Hospitals Protocol 1. Six normotensive, normocholesterolemic
Research Ethics Committees. healthy volunteers (3 male) were studied to determine
whether 10 g of l-arginine (Martindale Pharmaceuticals,
Assessment of conduit artery endothelial function Essex, UK) infused systemically was sufficient to over-
Endothelial function was determined by recording the come NOS inhibition. After measurement of basal radial
dilator response of the brachial or radial artery to in- artery FMD the NOS inhibitor, NGmonomethyl-l-arginine
creased blood flow generated during reactive hyperemia (l-NMMA), was infused via the upstream brachial artery
of the downstream forearm (brachial artery studies) or at a dose (4 mol/min) known from our previous studies
hand (radial artery studies). Subjects lay supine in a to induce maximal reduction of radial FMD [13]. After
temperature-controlled laboratory (22 to 25C). The bra- infusion of l-NMMA for ten minutes, radial artery FMD
chial or radial arteries of the non-fistula or non-dominant was recorded. Systemic l-arginine was then administered
arm were scanned in longitudinal section using a 7 MHz intravenously over 30 minutes in the contralateral arm,
linear array transducer and an XP 128/10 (Acuson), mag- after completing the infusion FMD was assessed again.
nified using a resolution box function and gated with the Protocol 2. This protocol was designed to determine
R wave of the electrocardiogram (ECG). End-diastolic the effect of systemic l-arginine on FMD of the brachial
images of the vessels were acquired every 3 seconds using artery in patients with dialysis-dependent renal failure.
data acquisition software (Information Integrity, Boston, Eighteen subjects (7 male) on renal replacement therapy
MA, USA) and stored off-line for later analysis. Arterial for at least three months were recruited and studied
diameter over a 1 to 2 cm segment was determined for immediately prior to a hemodialysis treatment. Brachial
each image using automatic edge detection software (In- artery FMD and blood flow were measured at baseline
formation Integrity). Analysis was performed by an ex- and ten minutes after completion of an intravenous infu-
perienced vascular technician blinded to the subject and sion of l-arginine (10 g in 100 mL of 0.9% saline over
order and repeated by a second investigator in a random 30 min). Because l-arginine has been reported to elevate
selection of one third of scans (studies where dilatation plasma potassium, subjects were excluded if serum potas-
differed by more than 1% were deemed technically inad-
sium was greater than 5.6 mmol/L at the time of study.
equate). Using pulsed wave Doppler, blood flow was
Mean arterial blood pressure was recorded using an au-recorded continuously throughout the study and was ex-
tomated oscillometric system (Dinamap vital signs moni-pressed as the velocity time integral (VTI; area under the
tor 1846 8X; GE Medical Instruments, Wisconsin, USA),blood velocity/time curve for a complete cardiac cycle).
and measurements obtained before and after each scanBaseline recordings of arterial diameter were made for
and at five-minute intervals throughout the l-arginineone minute before inflation of a blood pressure cuff placed
infusion using the non-study arm or the calf (in the pres-distal to the site of arterial imaging. Recording continued
ence of a fistula).for five minutes during cuff inflation to 300 mm Hg and
Protocol 3. This protocol was used to determine thefor four minutes after deflation. Endothelium-indepen-
effects of high local concentrations of l-arginine on con-dent dilation of the brachial artery was assessed by mea-
duit and resistance artery endothelial function in patientssuring the dilator response to a submaximal dose of the
with chronic renal failure, not yet receiving renal replace-nitric oxide donor, glyceryl trinitrate (GTN, 25g sublin-
ment therapy. Eight subjects (5 male) approaching end-gually). This elicited vascular dilation of the same order
stage renal failure (calculated GFR 20 mL/min esti-of magnitude as that of the endothelium-dependent flow
mated from plasma creatinine using the Cockcroft-Gaultstimulus (larger doses of GTN may fail to allow discrimi-
formula) were recruited. Figure 1 summarizes the experi-nation between subtle differences of intrinsic smooth
mental protocol. The brachial artery of the non-domi-muscle reactivity).
nant arm was cannulated and radial FMD was measured
Assessment of forearm blood flow (resistance during saline infusion. Then forearm blood flow response
vessel function) was measured during intrabrachial infusion of the endo-
thelium-dependent vasodilator acetylcholine (ACh; 25, 50,Mercury-in-silastic strain-gauge plethysmography was
100 nmol/min; each dose given for 3 min). l-arginine wasused to measure forearm blood flow (mL/100 mL of
infused via the brachial artery (50 mol/min) to achieveforearm/min) in both arms as described previously [11].
For each study, the brachial artery of the non-dominant a predicted local concentration of approximately 2 to 4
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Fig. 1. Experimental protocol 3. Effect of local intrarterial infusion of l-arginine on endothelial function of conduit and resistance arteries in
patients with predialysis renal failure.
Table 1. Subject characteristicsmmol/L [14]. Radial FMD and the dilator response to
ACh were determined in the presence of local l-arginine. Hemodialysis Pre-dialysis
Protocol 2 Protocol 3Biochemical measurements. Blood samples were taken
N18 N8before each study for analysis of total fasting cholesterol,
Age years 424 397creatinine, potassium and glucose. l-arginine and ADMA
MAP mm Hg 1062 10612
were measured by reverse-phase high-pressure liquid Cholesterol mmol/L 4.40.2 4.30.5
Creatinine lmol/L ESRF 58931chromatography (HPLC) before and 20 minutes after
Glucose lmol/L 4.20.2 5.60.5completion of the intravenous l-arginine infusion (pro- Potassium lmol/L 5.00.1 4.60.1
tocol 2) as previously described [15].
ESRF is end-stage renal failure and MAP is mean arterial pressure.
Calculations and statistics
For conduit vessel responses, the flow stimulus gener-
ated by reactive hyperemia was measured 5 seconds after (0.89  0.12 mol/L before and 0.99  0.05 mol/L
cuff release and subsequently at 15-second intervals for 90 after; N  18; P  0.4).
seconds. Dilation was expressed as the percentage change
Effect of systemic L-arginine on radial artery FMD infrom baseline diameter of the brachial or radial artery
the presence of NOS inhibition in healthy volunteers(mean  SEM) and analyzed by comparing both the
maximal dilation (mean of 3 consecutive observations) Protocol 1. Flow-mediated dilation of the radial artery
and also the area under the curve of dilation against was reduced by l-NMMA (6.8  1.6% before and 3.4 
0.9% after L-NMMA; N 6; P 0.01). L-arginine (10 gtime [AUC; units %(t)]. FMD and GTN dilation were
IV) fully restored FMD in the presence of l-NMMAcompared before and after l-arginine infusion. Using
(6.2  1.3%; N  6; P  0.05; Fig. 2). The flow stimulusvenous occlusion plethysmography for resistance vessel
was unaffected by l-NMMA or l-arginine infusion (datastudies, the dilator response to each dose of ACh was
not shown).derived from the ratio of blood flow in the infused/non-
infused (control) arm, as described previously [11]. Data
Effect of systemic L-arginine on brachial artery FMDwere compared using the two-tailed Student t test or by
in patients with dialysis-dependent renal failureanalysis of variance as appropriate. A P  0.05 was con-
Protocol 2. The flow stimulus generated during reac-sidered significant (Graph Pad Prism statistical package).
tive hyperemia before and after systemic l-arginine was
similar [peak VTI(m) before 0.27 0.03 and 0.26 0.03
RESULTS after; N  18; P  0.5; and the flow envelope over 90
The study population characteristics are outlined in seconds were similar; N 18; ANOVA P 0.1; Fig. 3A].
Table 1. In each group baseline arterial diameter, blood FMD did not increase after l-arginine infusion (4.1 
pressure and heart rate were similar before, during and 1.1% before and 3.0  1.2% after; N  18; P  0.07;
after drug infusions (data not shown). No studies were Fig. 3). Similarly, the area under the dilation time curve
excluded because of technical inadequacy. Intravenous before and after intravenous l-arginine infusion remained
l-arginine increased the plasma concentration fourfold unchanged (513.2  89.8% seconds before and 478.1 
(102.6  14.8 mol/L before and 405.4  34.2 mol/L 109.6% seconds after; N 18; P 0.6; Fig. 3C). Endothe-
lium-independent dilation in response to GTN was notafter; N  18; P  0.0001) but did not affect ADMA
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to restore a normal arginine/ADMA ratio in subjects
with chronic renal failure and to overcome the effect of
acute NOS inhibition in healthy volunteers. Despite this,
l-arginine did not improve FMD of the brachial artery
in patients on dialysis. Similarly, tenfold higher concen-
trations of l-arginine, delivered locally, had no effect on
radial FMD or resistance vessel response to acetylcholine
in patients with pre-dialysis renal failure. These observa-
tions suggest that competitive inhibition of NOS by circu-
lating toxins alone does not determine endothelium-
dependent dilation in patients with renal failure.
Endothelial dysfunction, assessed by measuring flow-
mediated dilation (FMD) of the brachial artery, has been
described in patients with renal failure [5–7]. FMD of
conduit arteries is largely dependent on NO generation
[16], and these studies implicate a reduction of NO syn-
Fig. 2. Competitive inhibition of nitric oxide synthase (NOS) by L-argi-
thesis or effectiveness in the vasculature of these pa-nine analogs is reversible in healthy volunteers. Flow-mediated dilation
(FMD) was reduced by NGmonomethyl-l-arginine (l-NMMA; P 0.01 tients. The generation of NO depends upon a continuing
by ANOVA) and restored by intravenous infusion of l-arginine (P  and renewable supply of the substrate, l-arginine. The
0.05 by ANOVA).
intracellular concentration of l-arginine is far in excess
of that needed to fully saturate endothelial NOS (eNOS),
and additional l-arginine would not be expected to in-
crease NO production. Nonetheless, l-arginine has beenaffected by l-arginine infusion (5.3  1.0% before and
reported to augment NO production in healthy humans4.5  0.8% after; P  0.2; Fig. 3B).
[17], in patients with hypercholesterolemia, and in smok-
Effect of local L-arginine on radial artery FMD ers [18–20]. One explanation for this apparent paradox
in pre-dialysis renal failure is that eNOS may be antagonized competitively by high
levels of naturally-occurring circulating metabolites. Ele-Protocol 3. The flow stimulus generated during reac-
vated levels of ADMA have been demonstrated in indi-tive hyperemia was similar before and after l-arginine
viduals with hypercholesterolemia and other risk factorinfusion (peak VTI 0.20  0.02 m before and 0.21 
cohorts for vascular disease [10, 21]. In patients with0.03 m after; N  8; P  0.5; and the flow envelopes
renal failure, circulating endogenous l-arginine analogs,over 90 seconds were similar; N 8; ANOVA; P  0.5).
including ADMA, are present in the plasma at concen-Radial FMD remained unchanged after intra-arterial
trations four to eightfold in excess of those seen in sub-l-arginine infusion (6.5  1.2% before and 6.3  0.8%
jects with normal renal function. This may account forafter; N  8; P  0.5; Fig. 4A).
reduced NO generation due to competitive inhibition of
Effect of local L-arginine on resistance eNOS resulting in a reduction of FMD.
artery endothelial function in pre-dialysis renal failure If competitive inhibition of NOS were an important
mechanism in the endothelial dysfunction of renal failureIntra-arterial l-arginine had no effect on baseline fore-
one would anticipate an improvement of endothelium-arm blood flow measured by venous occlusion plethys-
dependent dilatation after administration of exogenousmography. Mean baseline blood flow was 2.1  1.3
l-arginine. The present study used a systemic infusionmL/100 mL forearm/min before l-arginine and 2.2  1.0
of l-arginine to achieve an ADMA/l-arginine ratio com-mL/100 mL forearm/min after (P  0.1) (Fig. 4B). After
parable to that observed in healthy individuals [17]. Inco-infusion with l-arginine the dilator response did not
healthy volunteers, this dose of l-arginine overcame theincrease at any dose of ACh (P  0.4 by ANOVA), nor
effects of experimental NOS inhibition with l-NMMA,was there any improvement in a summary measure of
but the conduit artery and resistance vessel dilator func-the dose response curve expressed as AUC (23.1  6.4
tion did not improve in patients with dialysis-dependentunits before and 23.1  5.3 units after; N  8; P  0.9).
renal failure. This implies that endothelium dependent
dilation is not determined by the provision of exogenous
DISCUSSION l-arginine in this patient group.
Acute administration of l-arginine fails to improve The intravenous l-arginine infusion achieved systemic
arterial endothelial function in the conduit and resistance plasma concentrations in the micromolar range. Higher
vasculature of patients with renal failure. We have dem- systemic concentrations of arginine have been reported
to induce hyperkalemia and aggravate acidosis in pa-onstrated that the dose of l-arginine used was sufficient
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Fig. 4. Effect of intrabrachial infusion of L-arginine on vascular func-
tion in subjects with pre-dialysis renal failure. (A) Intrabrachial l-argi-
nine did not improve radial flow-mediated dilation (N  8; P  0.8).
(B) Intrabrachial l-arginine did not improve resistance vessel response
to the endothelium-dependent dilator acetylcholine (N  8; P  0.9).
Symbols are: () before infusion; () after infusion of l-arginine.
tients with renal failure. For this reason we explored
the effects of millimolar concentrations of l-arginine in
conduit and resistance arteries by local intra-brachial
infusion. Non-essential brachial artery cannulation in he-
modialysis patients is undesirable, and therefore, we
studied patients with severely impaired renal function
who would shortly require dialysis. Despite millimolar
concentrations of l-arginine, there was no increase in
FMD of the radial artery, or dilation of the resistance
vasculature in response to acetylcholine.
Our data suggest that in the short term, NOS inhibi-
tors, which compete with l-arginine, do not determine ar-
terial endothelial dilator function of patients with renal
Fig. 3. Effect of intravenous L-arginine in dialysis-dependent renal fail-
ure. (A) The velocity time integral [VTI(m)] was recorded for 90 sec-
onds after cuff release before () and after () intravenous l-arginine.
The flow stimulus was not affected by l-arginine infusion (N  18; N  18) in dialysis dependent subjects. (C ) Profile of FMD for the
ANOVA, P  0.1). (B) Intravenous l-arginine did not improve brachial 4 minute period after cuff release is shown before () and after ()
flow-mediated dilatation (FMD) or dilatation to glyceryltrinitrate (GTN; l-arginine infusion. L-arginine had no effect on dilation.
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